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Soldiers with catastrophic blood loss often die on the battlefield before they can be
evacuated. In an effort to translate the protective effects of AdenocaineTM
(adenosine, lidocaine and Mg2+) (ALM) from cardiac surgery to resuscitation
science, we examined the early hypotensive resuscitative effects of 7.5% NaCl with
ALM following near lethal blood loss of 60% in the rat model.
Methods: Male Sprague-Dawley rats (250–350g, n=32) were anesthetized and
randomly assigned to one of four groups: 1) Untreated, 2) 7.5% NaCl, 3) 7.5%
NaCl/6% Dextran-70 (RescueFlow®), 4) 7.5% NaCl/ALM. Shock was induced by
removing 60% blood (volume controlled) over 50 min and maintaining the MAP
between 30 to 40 mmHg. Animals were left in shock at 34°C for an additional 30
min. Total shock time was 80 min. 0.3 ml bolus was injected into the femoral
vein and hemodynamics monitored for 60 min (Phase 1). Shed blood was replaced
and function monitored for another 60 min (Phase 2). Lead II ECG, arterial
pressures, MAP, heart rate (HR) and rate-pressure product (RPP) were monitored.
Results: Mortality (%) for Untreated, 7.5% NaCl, 7.5% NaCl/6% Dextran-70, and
7.5% NaCl ALM groups were 100%, 75%, 87.5% and 0% respectively. Times to death
after bolus injection were 9±3, 19±4 and 45±12 min respectively. The MAP of
survivors at the end of Phase 1 was 24±3 (n=2), 26±0.1 (n=3) and 40±2 mmHg
(P<0.05) (n=8) respectively. After blood was returned, the MAP at 60 min for the
three treatment groups was 67±5 (n=2), 47 (n=1) and 69±5 mmHg (n=8)
respectively. All rats, except the 7.5% NaCl ALM group, were profoundly
proarrhythmic; Dextran doubled the arrhythmias compared with 7.5% NaCl alone.
No severe arrhythmias occurred in ALM group in Phase 1 or 2, and 60 min after
return of shed blood HR, MAP and RPP were 96%, 75% and 83% of their pre-shock
values.
Conclusions: Ultra-small (<1 ml/kg) IV bolus of 7.5% NaCl with ALM led to 100%
survival with no arrhythmias in Phase 1 following 60% blood loss. Compared to
untreated animals, 7.5% NaCl and the Dextran group delayed time to death by a
factor of 2 and 5 respectively. Only one rat receiving 7.5% NaCl/6% Dextran-70
survived and it was profoundly proarrhythmic. Further work is required to test if
7.5% NaCl ALM, with its low cube/high resuscitation capability, has field
applications.
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